CompletedPhase 3NCT01122771

Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Drugs for Neglected Diseases
Principal Investigator
Ridwanur Rahman, MD
Shaheed Surawardy Medical College
Intervention
Liposomal amphotericin B(drug)
Enrollment
602 enrolled
Eligibility
5-60 years · All sexes
Timeline
20102014

Study locations (4)

Collaborators

Shaheed Surhawardy Medical College and Hospital · International Centre for Diarrhoeal Disease Research, Bangladesh

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01122771 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis

← Back to all trials